Greater #comorbidity burden is assoc. w/ worse improvement and disease activity in 1st yr of treatment in ERA @earlyarthritis. Comorbidities esp affect SJC and patient and physician global assessments. #ACR21 Abs#0798 @RheumNow https://t.co/02BRqYp9Yk

• The Impact of Comorbidities on the Simple Disease Activity Index (SDAI) and Its…

#ACR21 Abst#0801 Early remission at 6 mos is a predictor of long-term remission in patients w new onset RA ▶️ DAS28-CRP, SDAI, CDAI at 6mo predicted remission at 60 months https://t.co/vWy7EmseZp @Rheumnow https://t.co/HWJSjvFY8d

• https://bit.ly/3CSPFNr

Good news for #COVID vaccine in #SLE. ✅doesn’t cause #lupus flares ➡️ no increase in APS. What about #SARS-CoV2 infection in SLE. Flares ↔️ stable but ⬆️APS Abs. from Hopkins cohort. Petri #ACRBest #ACR21 abst0858 @RheumNow https://t.co/ABx4C4lwvs

How can we better identify patients with #RA-ILD using #EHRs? Abs#0561: previously validated algorithms have clinical & research utility when applied to EHRs, esp when well-integrated with key info such as CT chest reports #ACR21 @RheumNow https://t.co/OU8BdwqHpc

• Enhancing the Identification of Rheumatoid Arthritis-Associated Interstitial Lu…

ADACTA & MONARCH both showed IL6i monoRx > TNFi monoRx for RA in DBRCTs. What about in real-world data? Looking at CorEvitas, less so LDA: aOR 0.99 MCID in CDAI: 1.06 Even without MTX, both great drug classes for RA Equally so? #ACR21 ABST0834 @RheumNow https://t.co/6wvzVrXTW6 https://t.co/fYEktJhZuV

• https://meet.acrconvergence.org/meetings/virtual/dSEeRFsuxifj8bZbz

#ACR21 A#0563 - Is FRAX score applicable for RA? 10 yr Olmsted County epi study: Yes ▶️ 76 osteoporotic fxs in RA pts, FRAX predicted 67 fx (SIR 1.13, not signif) ▶️ 21 observed hip fx, FRAX predicted 23.3 (SIR 0.9) ⭐️ No differences by ages/sex https://t.co/vWy7EmseZp @Rheumnow https://t.co/8BlzgQYqaV

• https://bit.ly/3CSPFNr

6 year f/up study of sacroilitis in nr-AxSpA pts ⭐️~10% of pts progressed from nr-AxSpa to AS every 2 years Abs#907 #ACR21 @RheumNow https://t.co/kiWGmKhpWu

• Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients …

Watch: What I'm Looking Forward to at #ACR21: Dr. Arthur Kavanaugh https://t.co/WygW1czwXn https://t.co/1qlZsFBd4Z

• https://bit.ly/3BVCr1g

Guidance on self-efficacy (SE) in IA were published this yr- what factors influence this? 👉PROMs & treatment response determine long-term SE 👉This may help identify pts benefitting most from interventions to improve SE Abs#0795 #ACR21 @RheumNow https://t.co/dx28WgxNsE https://t.co/7uN6XctnQb

• Treatment Response and Several Patient-reported Outcomes Are Early Determinants…

#ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX: ▶️No significant correlation between cumulative MTX dose and liver stiffness by fibroscan, even at high dose MTX. ⭐️Age, sex, waist circumference, BMI are risks @Rheumnow https://t.co/IhcNr9fhEh https://t.co/c7TUoGrNZ7

• https://bit.ly/3bLe4Jb

In Australia, there's free choice of originator vs biosimilar for etanercept. Real-world data shows exactly what you'd expect over >48 months - and sometimes it's what you expect that's exactly what you want to see... OPAL data #ACR21 0840 @RheumNow https://t.co/YJA2Cua9cw